生命科学资讯

The Bull Case For Illumina (ILMN) Could Change Following Buybacks And NovaSeq X Roadmap Reveal – Learn Why - simplywall.st

‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific

FDA fleshes out new roadmap for testing personalized therapies

Astellas pays $240M cash for Vir's prostate cancer drug

Waters Corporation to Present at the TD Cowen Health Care Conference - Yahoo Finance

Thermo Fisher Datavant Data Link Draws Focus To TMO Valuation And Risks - simplywall.st

QurAlis' ALS drug sees early positive signal, but questions remain

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Act

Fortress to sell priority review voucher for $205M

Waters Corporation (WAT) Stock Analysis: Unlocking 19.42% Potential Upside in the Healthcare Diagnostics Sector - DirectorsTalk Interviews

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

Appointments and advancements for Feb. 23, 2026

Financings for Feb. 23, 2026

In the clinic for Feb. 23, 2026

Other news to note for Feb. 23, 2026

Regulatory actions for Feb. 23, 2026

FDA unveils long-awaited guidance on new pathway for individualized therapies